Most Read Articles
Roshini Claire Anthony, 06 Oct 2020

Several strategies have been proposed to help manage the adverse events (AEs) that emerged during the BEACON CRC trial which assessed the effect of encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (mCRC) who had progressed after one or two prior regimens.

Pearl Toh, 15 Nov 2020
Switching to a dual therapy of dolutegravir/lamivudine (DTG/3TC) was noninferior to continuing on a TAF*-based regimen in maintaining virologic suppression over 96 weeks in virally suppressed adults with HIV-1, according to the long-term data from TANGO presented at the 2020 HIV Glasgow Congress.

Standardized order set during LVP safely lowers amount of albumin dosing

29 Sep 2020

Using an order set to guide albumin dosing based on the amount of ascitic fluid removed during large volume paracentesis (LVP) substantially reduces the quantity of albumin given with no difference in adverse effects, results of a study have shown.

The investigators examined the impact of implementing a standardized LVP order set on albumin utilization and patient outcomes in this retrospective review of patients with ascites due to cirrhosis who received a therapeutic paracentesis at a large, academic institution. Albumin doses were standardized in the order set to 25 g (5-6 L removed), 50 g (7-10 L), and 75 g (>10 L).

The amount of albumin used prior to and after order set implementation was the primary outcome. Other patient outcomes included rates of hyponatraemia, renal impairment, and hypotension.

Each arm included 100 patients in the final analysis. Patients prior to order set implementation received a higher amount of albumin per litre removed than those postimplementation (8.3 vs 6.5 g/L; p<0.01).

No significant between-group differences were seen in absolute changes in serum sodium (0 vs −1 mEq/L; p=0.64), serum creatinine (0.06 vs 0.05 mg/dL; p=0.94), or systolic blood pressure (−4 vs −3 mm Hg; p=0.96). No differences were also noted in rates of hyponatraemia (1.6 percent vs 6.6 percent; p=0.21), renal impairment (11.3 percent vs 11.5 percent; p=0.97), or hypotension (17.4 percent vs 17.6 percent; p=0.97) between the two groups.

“Albumin after LVP reduces paracentesis-induced circulatory dysfunction. The most efficacious dose of albumin for LVP is unclear,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 06 Oct 2020

Several strategies have been proposed to help manage the adverse events (AEs) that emerged during the BEACON CRC trial which assessed the effect of encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (mCRC) who had progressed after one or two prior regimens.

Pearl Toh, 15 Nov 2020
Switching to a dual therapy of dolutegravir/lamivudine (DTG/3TC) was noninferior to continuing on a TAF*-based regimen in maintaining virologic suppression over 96 weeks in virally suppressed adults with HIV-1, according to the long-term data from TANGO presented at the 2020 HIV Glasgow Congress.